Index rekommenderas avsluta studie: ”Överraskande och nedslående”

En oberoende kommitté rekommenderar Index Pharmaceuticals att avbryta sin fas III-studie med läkemedelskandidaten Cobitolimod, som prövas som behandling mot ulc...

Pfizer värvar FDA-topp – kritiseras hårt

Läkemedelsjätten Pfizers rekrytering av Patrizia Cavazzoni, tills helt nyligen toppchef vid FDA, som ny medicinsk chef får frän kritik från flera håll.

Moderna develops mRNA vaccine against norovirus

A highly anticipated vaccine is in late clinical evaluation and could be ready for approval within a couple of years. The target is the norovirus, often called ...

Norwegian cancer research companies merge

The Norwegian companies Ultimovacs and Zelluna Immunotherapy plan to merge. At the same time, it is made clear that Ultimovacs' CEO is leaving the company.

Lösning hittad för Orexos patenttvist

En långdragen patenttvist mellan Uppsalabolaget Orexo och indiska Sun Pharmaceutical Industries är nu löst genom förlikning.

Life science trends 2025 – The economy

Upcoming patent expirations are driving pharmaceutical companies to acquire in 2025. In Sweden, we may be on our way to brighter times and fewer bankruptcies. T...

MSD discontinues development of cancer drugs after trial failures

MSD suspends Phase 3 trials for two drug programs for different forms of cancer after trial failures.

Index Pharmaceuticals tecknar japanskt licensavtal

Svenska läkemedelsutvecklaren Index Pharmaceuticals har nu tecknat ett licensavtal med Viatris Japan.

The new ZEISS Celldiscoverer 7 has been launched

Adaptable automation for advanced workflows.

600 million SEK for life science - "Should not be the country of moderation"

Sweden will prioritize excellence over breadth in research. This was made clear when the government presented the research proposition for the next four years.

Bredd och spets på välbesökt life science-event

Hela kedjan inom läkemedelsframställning – från den tidiga forskningen till fyllning av vialer – var representerad när konferensen New Horizons in Biologics & B...

Lilly´s Nordic manager on Mounjaro launch in Sweden: "Patients deserve respect"

Another blockbuster diabetes and obesity drug has made its way into the Swedish market – with promises of a stable supply and availability for patients. “What w...

Bolag anklagas för att ha mörkat förhöjd risk för deltagare i alzheimerstudier

Ett stort antal deltagare i de kliniska alzheimerstudierna av lecanemab och donanemab bar på en genvariant som gjorde att de löpte förhöjd risk för allvarliga b...

Pneumatics Makes a Technological Leap with Piezo

The first high-precision proportional valve terminal VTEP opens up new application areas

Explore the latest trends and innovations in quality assurance and manufacturing

ZEISS QUALITY INNOVATION SUMMIT in Berlin, October 22-24, 2024.

Bioscience – Groundbreaking Research & Diagnostics: Stockholm

Rise and Scantox cease conducting animal testing in Stockholm

Access to in vivo toxicology services is significantly decreasing in the Stockholm area as Rise shuts down animal testing and Scantox reorganizes. ”The costs ar...

From powder to implant

Quality assurance for additively manufactured implants.

Nytt varsel på BMS – ska spara 1,5 miljarder

Bristol Myers Squibb, BMS, varslar 195 anställda efter att läkemedelsbolaget genomför ytterligare ett besparingspaket.

Who pays for Rebecca Doe – and all of us?

Anna Törner on how easily we get used to the idea that healthcare is free - when it really is about how and who pays for it

Basics of Confocal Laser Scanning Microscopy

Learn about the principle of confocal fluorescence microscopy.

Anna Törner: ”If I fall seriously ill, I’ll move to Finland”

”It is both undignified and undemocratic that cancer patients must travel to Finland to uphold a façade of fairness that does not truly exist”, Anna Törner writes in a column.

J & J och Bayer säger upp personal

Närmare 300 jobb inom läkemedelsindustrin i New Jersey försvinner när Johnson & Johnson och Bayer skär ner.

Joy at Egetis after positive CHMP opinion – ”The single most important milestone”

Stockholm-based Egetis Therapeutics has received a positive CHMP opinion for Emcitate, which could become the first approved treatment for the rare disease MCT8 deficiency."